Search Bar & Filters
Found 131 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of delgocitinib cream applied twice daily to treat adults with mild to severe lichen sclerosus LS, focusing mainly on female participants since LS is more common in females. This Phase 3 trial is designed to assess the efficacy and safety of delgocitinib in comparison to a cream vehicle over a long period. The study includes two parts Part 1 enrolls females to determine the best dose, and Part 2 enrolls both males and females to further evaluate safety and efficacy. Participants will be assigned randomly to receive either delgocitinib cream at specified doses or a cream vehicle. Treatments are applied twice daily during an initial 12-week period followed by a continuation treatment period lasting 40 weeks. Various dosing regimens are used across groups, including delgocitinib cream alone, cream vehicle alone, or combinations transitioning between the two during the study. Male participants will be included in a substudy to evaluate delgocitinibs effects in men. During the trial, participants will attend clinic visits and undergo assessments including measurement of skin condition severity using the IGA-LS score, clinical lichen sclerosus score CLISSCO, and patient-reported scales for skin pain and itch. Quality of life related to vulvar symptoms will also be monitored. Safety is carefully tracked through adverse event reporting and laboratory tests throughout the study, which lasts from 55 to 60 weeks per participant. The primary outcome is the number of participants achieving a specific improvement in LS severity at week 12.
Actively Recruiting
Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.
Actively Recruiting
This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.
Actively Recruiting
This research aims to observe the long-term safety of efgartigimod treatment in adults with generalized myasthenia gravis gMG. It compares patients who are starting or have recently started efgartigimod treatment with those who have not been exposed to efgartigimod and are receiving other standard treatments. The study is non-interventional and prospective, focusing on real-world safety outcomes over an extended period. Participants are divided into two groups one receiving efgartigimod and another receiving other medications for myasthenia gravis. This study does not involve any new treatments being administered as part of the trial but monitors patients during their routine care. The study will continue for up to 10 years to gather long-term safety data. During the study, researchers will track the occurrence of serious infections and other safety concerns in both groups. Patients will be monitored through their regular clinical visits without additional interventions from the study. Participants may be followed for up to 10 years to assess safety outcomes associated with their treatments in everyday medical practice.
Actively Recruiting
Researchers are evaluating IM-101 in adults with generalized myasthenia gravis gMG and ocular myasthenia gravis oMG, focusing on those with acetylcholine receptor AChR antibody-positive and AChR antibody-negative forms. The goal is to assess the safety, tolerability, how the drug moves through and affects the body, and the potential effectiveness of IM-101. This Phase 1b2 trial is sponsored by ImmunAbs Inc. and includes multiple study parts to explore these aspects thoroughly. Participants will receive IM-101 or a placebo through intravenous infusions. In Part A, participants get a loading dose on Day 1 and Day 15, followed by a maintenance dose on Day 29, with doses escalating across cohorts. In Part B, dosing includes loading doses on Day 1 and Day 15 and maintenance doses on Days 29, 57, and 85. Some may receive additional doses depending on decisions by an independent data monitoring committee. The study uses randomized, double-blind assignments to compare different dose levels and placebo effects. During the study, participants will be monitored for side effects and safety up to about 99 days in Part A and 169 days in Part B. Researchers will assess the impact of treatment on daily living activities and specific myasthenia gravis severity scores at baseline and Week 16. Safety assessments include tracking adverse events, serious adverse events, and events leading to discontinuation. Participants will undergo regular evaluations to measure the pharmacokinetics and pharmacodynamics of IM-101, with follow-up visits scheduled according to the dosing timeline.
Actively Recruiting
Researchers are studying the safety and effectiveness of NEU-411 in people aged 40 to 80 years with early Parkinsons Disease PD who have a specific genetic profile that predicts increased activity in the LRRK2 pathway. This Phase 2 study uses a companion diagnostic genetic test to identify participants with LRRK2-driven PD. The trial aims to compare NEU-411, a brain-penetrant drug that inhibits LRRK2 activity, to a placebo. Participants will be randomly assigned to receive either NEU-411 30 mg once daily or a matching placebo for 52 weeks. After this double-blind treatment period, there will be a safety follow-up visit within two weeks. Those who qualify may continue into an open-label extension phase where they will receive NEU-411 for an additional 26 weeks. Throughout the study, participants will have their Parkinsons symptoms and safety monitored using digital biomarker scores and clinical rating scales. Researchers will assess changes from baseline in the Roche digital biomarker score and the Unified Parkinsons Disease Rating Scale over the 52-week treatment period. Safety will be tracked by recording adverse events through the end of the study. Total participation may last up to 78 weeks including the extension and follow-up.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of intravenously administered YN001 in adults diagnosed with coronary atherosclerosis who are also receiving treatment for cardiovascular risk factors. This multinational, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial aims to compare different doses of YN001 with placebo in this population. Participants will be randomly assigned to receive one of three weekly intravenous treatments YN001 at 40mg, YN001 at 20mg, or a placebo at 0mg. Treatment will be administered once weekly for 13 weeks, totaling 13 doses. The study includes a screeningbaseline period lasting up to 12 weeks, a 12-week blinded treatment phase, followed by a 30-day safety follow-up and a long-term monitoring period lasting approximately 2 years after randomization. During the study, participants will undergo various assessments including imaging scans to measure changes in coronary and carotid artery plaque, blood tests to analyze YN001 concentration and immune responses, and monitoring for major adverse cardiac events. The primary measurement is the relative change in coronary non-calcified plaque volume from baseline to week 13. Safety and immune response will be closely tracked throughout treatment and follow-up, with total participation lasting up to about 2 years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ENV-294, an oral investigational drug, in adults with moderate-to-severe atopic dermatitis AD. This double-blind, placebo-controlled Phase 2b study compares three different doses of ENV-294 against a placebo over 12 weeks. The study aims to better understand how ENV-294 affects disease severity, symptoms, quality of life, and biological markers in people with chronic AD. Participants will be randomly assigned to one of four groups receiving either one of three doses of ENV-294 or a matching placebo. The treatment is taken once daily by mouth for 12 weeks. Before starting treatment, participants undergo screening to confirm eligibility based on their AD diagnosis, disease severity, and treatment history. During the study, participants complete regular assessments of their eczema severity using standardized scores like the Eczema Area and Severity Index EASI, patient-reported outcomes, safety checks, blood tests for drug levels, and biomarker analysis. Researchers monitor for any adverse events throughout the 12 weeks and for an additional 4 weeks following treatment. The total participation time includes screening, treatment, and follow-up assessments to evaluate both the effects and safety of ENV-294.
Actively Recruiting
Researchers are evaluating Rezpegaldesleukin as a treatment for people aged 12 years and older who have moderate to severe atopic dermatitis. This Phase 3, randomized, double-blind study compares Rezpegaldesleukin to a placebo to assess its effect on this skin condition. The overall participation lasts about 15 months. Participants will receive Rezpegaldesleukin or placebo injections during an induction period every 2 weeks. Afterward, during the maintenance period, Rezpegaldesleukin is given every 4 or 12 weeks, while placebo is given every 4 weeks. There is also an open-label escape phase where dosing frequency is decided by the investigator. Treatments are given by subcutaneous injection. During the study, participants will undergo assessments including the Investigators Global Assessment IGA score, Eczema Area and Severity Index EASI, itch and skin pain scales, sleep quality questionnaires, and asthma and nasal symptom scores. These evaluations happen at baseline, Week 6, and Week 24. Safety is monitored throughout, with adverse events recorded until about Week 56. Participants are followed for approximately 15 months in total.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of claseprubart in adults with generalized myasthenia gravis gMG in this Phase 3 study. The trial aims to demonstrate how claseprubart affects daily living activities and muscle strength in participants diagnosed with gMG. Participants are randomly assigned to receive either an intravenous IV loading dose of claseprubart or placebo on Day 1, followed by subcutaneous SC injections of claseprubart or placebo every two weeks starting at Week 1. The study includes a screening period of up to 12 weeks, a 17-week randomized, blinded, controlled treatment period, an optional extended treatment period lasting 104 weeks with blinded and open-label extensions, and a 40-week safety follow-up phase. During the study, participants undergo various assessments including the Myasthenia Gravis Activities of Daily Living MG-ADL scale, Quantitative Myasthenia Gravis QMG scale, and Myasthenia Gravis Composite MGC scale. Researchers also monitor treatment-emergent adverse events, serum concentrations of claseprubart, complement blood test changes, and antibody development against the drug. The total participation can last up to approximately 161 weeks, covering all study phases and follow-up.
1-10 of 131
1